

**CLEAN VERSION OF REWRITTEN OR ADDED CLAIMS
PURSUANT TO 37 CFR § 1.21 (c)(1)(i)**

BEST AVAILABLE COPY

Please amend the following claims:¹

E1
22. (Twice Amended) A solution for the treatment of a microbial infection, said solution comprising a sterile liquid vehicle and a leukotriene dissolved in said sterile liquid vehicle, wherein said solution is an aerosol.

E2
28. (Twice Amended) A solution for the treatment of a microbial infection, said solution comprising a sterile liquid vehicle and a leukotriene dissolved in said sterile liquid vehicle, wherein said solution is in an intratracheal instillation device, said instillation device is selected from the group consisting of an endotracheal tube and a bronchoscope.

E3
33. (Amended) A composition for the treatment of a microbial infection comprising, a sterile liquid vehicle and a leukotriene dissolved in said sterile liquid vehicle, wherein said solution is contained within a nebulizer.

¹ The amendments are made to clarify one particular embodiment, and are not to be interpreted as acquiescing to the Examiner's argument but to further the prosecution, and hereby expressly reserving the right to prosecute the original (or similar) claims,

**CLEAN VERSION OF REWRITTEN OR ADDED PARAGRAPHS
PURSUANT TO 37 C.F.R. § 1.121(b)(1)(ii)**

Please add the following:

BEST AVAILABLE COPY

Page 1 Para 1.

Related Applications

This is a Divisional of copending application 08/757,136 filed on 12/03/96 issued as
Patent No. 5,909,734 on 06/08/99.

E4

APPENDIX II
CLEAN VERSION OF THE ENTIRE SET OF PENDING CLAIMS
PURSUANT TO 37 CFR § 1.121 (c)(3)

22. A solution for the treatment of a microbial infection, said solution comprising a sterile liquid vehicle and a leukotriene dissolved in said sterile liquid vehicle, wherein said solution is an aerosol.

BEST AVAILABLE COPY

23. The solution of Claim 22, wherein said leukotriene is leukotriene B₄.
24. The solution of Claim 22, wherein said leukotriene is a cysteinyl leukotriene.
25. The solution of Claim 24, wherein said cysteinyl leukotriene is selected from the group consisting of leukotriene C₄, leukotriene D₄, and leukotriene E₄.
27. The solution of Claim 22, wherein said microbial infection comprises *Klebsiella pneumoniae* infection.
28. A solution for the treatment of a microbial infection, said solution comprising a sterile liquid vehicle and a leukotriene dissolved in said sterile liquid vehicle, wherein said solution is in an intratracheal instillation device, said instillation device is selected from the group consisting of an endotracheal tube and a bronchoscope.
29. The solution of Claim 28, wherein said leukotriene is leukotriene B₄.
30. The solution of Claim 28, wherein said leukotriene is a cysteinyl leukotriene.
31. The solution of Claim 28, wherein said cysteinyl leukotriene is selected from the group consisting of leukotriene C₄, leukotriene D₄, and leukotriene E₄.
32. The solution of Claim 28, wherein said microbial infection comprises *Klebsiella pneumoniae* infection.

- BEST AVAILABLE COPY**
33. A composition for the treatment of a microbial infection comprising, a sterile liquid vehicle and a leukotriene dissolved in said sterile liquid vehicle, wherein said solution is contained within a nebulizer.
 34. The composition of Claim 33, wherein said leukotriene is leukotriene B₄.
 35. The composition of Claim 33, wherein said leukotriene is cysteinyl leukotriene.
 36. The composition of Claim 33, wherein said cysteinyl leukotriene is selected from the group consisting of leukotriene C₄, leukotriene D₄ and leukotriene E₄.
 37. The composition of Claim 33, wherein said microbial infection comprises *Klebsiella pneumoniae* infection.